Grail Inc (GRAL) Stock Analysis
Verdict: HOLD
FDA panel catalysts drive rally momentum, but missing trial endpoints, heavy insider selling, and $320M annual cash burn pose severe downside risk.
Investment score: 46/100
Analysis as of
Is Grail Inc stock worth reviewing? AI model thesis
The model score of 46/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Grail Inc opportunities and risks
What speaks for GRAL
- Commercial test volume growth
What speaks against GRAL
- Binary FDA Advisory Committee decision risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GRAL | n/a | 34.4x | n/a | -10.8% | -236.9% | -5.2% |
| IMVT | n/a | 974.3x | n/a | 97.1% | -7585.9% | -6.0% |
| RYTM | n/a | 28.2x | n/a | 89.0% | -85.6% | -2.2% |
| CGON | n/a | 985.8x | n/a | -82.7% | -3602.7% | -2.9% |
| SRRK | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.0% |
| TVTX | n/a | 9.7x | 4031.6x | 94.4% | -7.4% | 0.9% |
| Peer median | n/a | 28.2x | n/a | 89.0% | -85.6% | -2.9% |
Frequently asked questions about Grail Inc (GRAL)
Is GRAL stock a good investment?
The cached TradeMates AI model rates Grail Inc as HOLD with an investment score of 46/100. The model score of 46/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is GRAL stock a buy?
The TradeMates model verdict for GRAL is HOLD with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.